Predict neutropenia, severe anemia, or thrombocytopenia at the preclinical drug development stage.
We have decades of experience performing these assays, so you can trust our cell culture proficiency and lineage-specific colony scoring accuracy. CFC assay data can support your IND submission and these assays are often required by regulatory agencies. CFC assays are highly effective in predicting toxicity at the bone marrow hematopoietic progenitor cell level and can be utilized to evaluate drug efficacy against blood cancer progenitor cells.
Discovery’s expert cell biologists have developed numerous novel assays, enabling us to offer a broader and more strategic array of services to our clients. Our ongoing innovations accelerate drug discovery and development, ultimately enhancing patient outcomes.
Dr. Clarke has over 25 years of experience in stem cell biology, spanning both clinical and industrial settings. She plays a pivotal role in driving innovations and managing Discovery’s scientific operations, including research and development and client services. Dr. Clarke is also actively involved in client affairs, offering one-on-one consultations, study design, and data analysis.
The preclinical screening method that helps clients eliminate bad players earlier in the drug development process. White Paper
Colony Forming Cell assays can predict compound induced toxicities including neutropenia, thrombocytopenia, anemia and lymphotoxicity. Video
The haematotoxic potential of xenobiotics is determined by the evaluation of the inhibition of CFU-GM growth. White Paper
Join Discovery Life Sciences at Phacilitate's Advanced Therapies Week 2025, Jan 20-23 in Dallas! Visit us at Booth 161 and join Dr. Yuki Maves' presentation on Jan 23. Supply Chain: […]
Join Discovery at Precision Medicine Tri-Con 2025.
Join Discovery at World CB & CDx Summit Europe 2025.
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
